AssayIndex

AX-2024-004595

Enclomiphene citrate · 50 mg declared · Tianjin Finder Chemical Co., Ltd. · lot TFC-2404-J9626

FAILPARTIAL
Report ID
AX-2024-004595
Compound
Enclomiphene citrate
Compound class
Non-peptide adjuncts
Supplier
TFC — Tianjin Finder Chemical Co., Ltd.
Batch / lot
TFC-2404-J9626
Declared label claim
50mg
Laboratory
Janoshik Analytical
Assay date
19 Aug 2024
Submitted
14 Sep 2024
Quarter
2024-Q3
Submitter
d.restrepo
Sample provenance
Buyer-sourced
Section 1

Results

Measured against the index acceptance specification for the non-peptide adjuncts class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

ParameterMethodResultUnitIndex spec
PurityRP-HPLC, 30 min gradient, 214 nm99.16% area≥ 98.5PASS
Total impuritiesRP-HPLC, sum of reported peaks0.84% area≤ 1.5PASS
Largest single impurityRP-HPLC — N-oxide (+16 Da)0.52% area≤ 1.00PASS
Identity — theoretical monoisotopic masscalculated from molecular formula597.2130DaNOT TESTED
Identity — observed monoisotopic massLC-MS, high resolution (ESI-TOF/QTOF)597.2113DaNOT TESTED
Mass accuracyobserved vs theoretical-2.9ppm± 10PASS
Total peptide contentby difference from the gravimetric mass balance63.61%w/wNOT TESTED
Target-compound contenttotal peptide content × purity63.08%w/wNOT TESTED
Gross fill (as weighed)five-place balance, under nitrogen83.77mg50 mg declaredNOT TESTED
Recovered target peptidegross fill × target content52.842mg50 mg claimNOT TESTED
Recovery against label claimrecovered ÷ claim105.7%90.0 – 110.0PASS
Water contentKarl Fischer, coulometric, duplicate3.82%≤ 10.0PASS
Counter-ion (citrate)anion-exchange ion chromatography31.91%≤ 12.0FAIL
Residual solvent + inorganic residueestimated — see /methods/residual-solvents-q3c/0.66%NOT TESTED
Endotoxinnot ordered on this submissionnot determined≤ 5.0NOT TESTED
Sterilitynot ordered on this submissionnot determinedno growthNOT TESTED
Appearancevisual, diffuse light, black and white backgroundWhite lyophilised cake, intactwhite to off-white intact cakePASS
Reconstitution clarityreconstituted per submitter procedureClear, colourless, no visible particulatesclear, no visible particulatesPASS
pH (reconstituted, 1 mg/mL)potentiometric, two-point calibration4.832.5 – 8.0PASS
Retention time (observed)RP-HPLC, 30 min gradient16.35min16.44 ± 0.35 (normalised)PASS
Peak asymmetry (10 % height)Ph. Eur. 2.2.461.130.80 – 1.50PASS
Plate count, main peakN = 5.54 (t/w½)²95,986≥ 20,000PASS
Resolution to nearest impurityvs free base (des-citrate)0.09no index criterionREPORTED
Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

02043408661298172 Enclomiphene citrate16.35 min · 99.16 % 15.47 same trace · ×100 vertical expansion, baseline-corrected · main peak off-scale reporting threshold 0.05 % area 05101520253035 Retention time (min) Response (mAU)
Figure 1. RP-HPLC trace, 30 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 95,986, and skew follows the reported asymmetry factor of 1.13. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.52 % impurity against a 99.16 % main peak is a line two pixels tall; the main peak runs off-scale there by design.
#PeakRTArea (µV·s)% areaΔ mass (Da)
1Enclomiphene citrate — main peak16.354,819,48399.16
2N-oxide (+16 Da)15.4725,2740.52+15.995
3des-ethyl enclomiphene (−28 Da)15.918,7490.18-28.031
4zuclomiphene (cis-isomer)15.734,8600.100.000
5free base (des-citrate)16.371,9440.04-192.027
Closure check — purity + Σ impurities 100.00CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 597.2130 Da, computed from C26H28ClNO · C6H8O7. All ppm figures on this site are against monoisotopic values — see why that matters.

0255075100550575600625650675 [M+1H]1+598.22 m/z Relative abundance (%)
Figure 2. ESI charge-state envelope, high-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 597.2113 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.
ChargeTheoretical m/zObserved m/zΔ m/zRel. abundance (%)
1+598.2203598.2186-0.0017100.0
Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

ComponentDetermination%w/w of cake
WaterKarl Fischer3.82
Counter-ion (citrate)ion chromatography31.91
Residual solvent + inorganic residueestimated0.66
Total peptide contentby difference63.61
Total100.00 CLOSES

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

FigureSupplier COAThis reportIndex note
Purity (% area)99.1099.16divergence -0.34 pp vs batch median
Total impurities (% area)not stated0.84
Largest single impurity (% area)not stated0.52
Water (%)not stated3.82
Counter-ion (%)not stated31.91
Peptide content (%w/w)91.763.61
Endotoxin (EU/mg)0.67not determined
Method stated on certificateYEScolumn, gradient and wavelength given
Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance
Buyer-sourced
Evidentiary weight
Strongest available evidence in this index.
Chain of custody
Domestic warehouse despatch → submitter (2–8 °C, 12 d) → laboratory (courier, cold pack, 9 d) → assay.
Assay date
19 Aug 2024
Submitted to the index
14 Sep 2024
Laboratory
Janoshik Analytical, Ostrava, Czechia
Method basis
30 min gradient · high-resolution MS
Verification status
PARTIAL
Section 6

Annotations 2

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

survivor_lots
Even a perfectly blind purchase is a lot somebody chose to test. Provenance fixes one selection problem and leaves the other standing.
label_claim
A retail vial is also a test of the label. Declared claim 50 mg against what the gravimetry recovers is a question only a purchased vial can answer honestly.
Section 7

Related records

Same batch — lot TFC-2404-J9626 n=11

ReportLotLabQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2024-004592TFC-2404-J9626Janoshik2024-Q399.443.91102.6Buyer-sourced0FAIL
AX-2024-004593TFC-2404-J9626Janoshik2024-Q399.283.4990.0Buyer-sourced0FAIL
AX-2024-004594TFC-2404-J9626Janoshik2024-Q399.433.86Buyer-sourced0FAIL
AX-2024-004596TFC-2404-J9626VendorInvestigate2024-Q399.833.3691.5Buyer-sourced1FAIL
AX-2024-004597TFC-2404-J9626VendorInvestigate2024-Q398.863.89Buyer-sourced0FAIL
AX-2024-004598TFC-2404-J9626Janoshik2024-Q399.484.13Buyer-sourced0FAIL
AX-2024-004599TFC-2404-J9626Kestrel2024-Q399.504.5297.6Buyer-sourced1FAIL
AX-2024-004600TFC-2404-J9626Janoshik2024-Q399.583.92Buyer-sourced0FAIL
AX-2024-004601TFC-2404-J9626Janoshik2024-Q399.543.74Supplier-supplied0FAIL
AX-2024-004602TFC-2404-J9626Janoshik2024-Q399.093.64101.9Buyer-sourced0FAIL
Other recent Enclomiphene citrate records in the index.
ReportSupplierLotLabQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2026-041525QSCQSC-2604-R6644PeptideMeter2026-Q299.804.04101.5Laboratory-retained0FAIL
AX-2026-042329TFCTFC-2605-H2745Nordanalyt2026-Q299.413.67Buyer-sourced2FAIL
AX-2026-041524QSCQSC-2604-R6644PeptideMeter2026-Q299.934.6091.6Buyer-sourced0FAIL
AX-2026-041526QSCQSC-2604-R6644Medutest2026-Q299.684.25103.7Buyer-sourced1FAIL
AX-2026-043164SSASSA-2603-C7061Kestrel2026-Q298.483.27107.4Buyer-sourced2FAIL
AX-2026-041773ASYASY-{CAT}-1806Janoshik2025-Q499.883.59Buyer-sourced1FAIL
AX-2025-019360HYBHYB-2510-J6404Medutest2025-Q499.615.0798.1Laboratory-retained0FAIL
AX-2025-018986ASYASY-{CAT}-1806Medutest2025-Q499.933.35Buyer-sourced1FAIL
Other recent TFC records in the index.
ReportCompoundLotLabQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2026-042265Humanin (HNG)TFC-2605-U1300PeptideMeter2026-Q399.526.31Buyer-sourced0PASS
AX-2026-042222SS-31 (Elamipretide)TFC-2607-R9099VendorInvestigate2026-Q399.465.41102.6Buyer-sourced0PASS
AX-2026-042236Humanin (HNG)TFC-2608-S9940Nordanalyt2026-Q398.641.80Buyer-sourced0PASS
AX-2026-042282RetatrutideTFC-2608-J1156Janoshik2026-Q398.544.27Buyer-sourced0PASS
AX-2026-042226SS-31 (Elamipretide)TFC-2607-R9099Janoshik2026-Q399.625.47Buyer-sourced0PASS
AX-2026-042217SemaglutideTFC-2604-X9037PeptideMeter2026-Q398.954.6196.9Buyer-sourced0PASS
AX-2026-042339SermorelinTFC-2605-Y2176Kestrel2026-Q399.934.14Supplier-supplied1FAIL
AX-2026-042214SemaglutideTFC-2604-X9037Kestrel2026-Q399.874.66103.1Laboratory-retained0PASS